rosiglitazone has been researched along with Cirrhosis in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (18.18) | 29.6817 |
| 2010's | 24 (72.73) | 24.3611 |
| 2020's | 3 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Amaudrut, J; Barth, M; Binet, J; Boubia, B; Broqua, P; Chatar, M; Dodey, P; Ferry, S; Gauthier, E; Guillier, F; Jacquier, E; Junien, JL; Lacombe, O; Legendre, C; Lepais, V; Llacer, J; Luccarini, JM; Masson, P; Montalbetti, C; Mounier, L; Peralba, P; Poupardin, O; Thourigny, A; Wettstein, G | 1 |
| Chen, Y; Dai, Y; Gao, H; Huang, Y; Jin, R; Mo, D; Yan, Q; Zhang, C; Zhang, L | 1 |
| Aceves, SS; Dohil, L; Dohil, R; Hsieh, L; Kurten, R; Moawad, FJ; Newbury, RO; Nhu, QM | 1 |
| Shi, Z; Wei, S; Wu, M; Xu, C; Yang, B; Zhang, Y | 1 |
| Heeringa, P; Kleemann, R; Kooistra, T; Liang, W; Morrison, MC; Salic, K; Tomar, T; van Koppen, A; Wielinga, PY; Yakala, GK | 1 |
| Hahm, KB; Hong, SP; Jung, Y; Kim, DH; Kim, G; Kim, JW; Koo, JB; Lee, KJ; Lee, KM; Nam, MO; Shin, SJ; Yoo, J; Yoo, JH | 1 |
| Huxlin, KR; Jeon, KI; Phipps, RP; Sime, PJ | 1 |
| Kim, SW; Nuwormegbe, SA; Sohn, JH | 1 |
| Chen, N; Liu, J; Wang, W; Zhang, L; Zhou, F | 1 |
| Abdel, MP; Arsoy, D; Berry, DJ; Lewallen, EA; Limberg, AK; Morrey, ME; Reina, N; Salib, CG; Sanchez-Sotelo, J; Tibbo, ME; Trousdale, WH; van Wijnen, AJ; Viste, A; Yaszemski, MJ | 1 |
| Deng, J; Shao, M; Shao, X; Wang, X; Xia, Y; Xiong, C; Zhou, Q; Zou, H | 1 |
| Huang, Q; Li, D; Li, T; Li, Z; Lu, Y; Pan, Z; Wu, H; Yang, T; Yang, W; Zhan, L; Zhang, G; Zhuang, Y | 1 |
| Cao, M; Duan, X; Liu, K; Pan, Z; Qu, J; Zhang, F; Zhou, D; Zhou, Y | 1 |
| Cao, M; Duan, X; Huang, Y; Liu, H; Liu, K; Pan, Z; Zhang, F; Zhou, D | 1 |
| Hindman, HB; Huxlin, KR; Jeon, KI; Kulkarni, A; Phipps, RP; Sime, PJ; Woeller, CF | 1 |
| Korantzopoulos, P; Li, G; Li, J; Liu, T; Zhao, H | 1 |
| Fu, L; Gao, X; Li, H; Liu, C; Mei, C; Wang, X; Yang, M; Yuan, L | 1 |
| Bai, M; Chen, Y; Ding, G; Huang, S; Jia, Z; Xu, Y; Zhang, A; Zhang, Y; Zhao, M | 1 |
| Chang, E; Ghosh, AK; Melichian, DS; Varga, J; Warner-Blankenship, M; Wu, M | 1 |
| Baek, SH; Chang, K; Ihm, SH; Kim, HY; Kim, JH; Seung, KB; Youn, HJ | 1 |
| Abraham, DJ; Denton, CP; Eastwood, M; Leask, A; Shi-wen, X; Stratton, RJ | 1 |
| Kaur, T; Pal Singh, A; Singh Bedi, PM; Singh, N; SinghDahiya, R | 1 |
| Aguila, MB; Mandarim-de-Lacerda, CA; Torres, Tda S | 1 |
| Abassi, Z; Collins-Racie, L; Diblasio-Smith, L; Feuerstein, GZ; Goltsman, I; Lavallie, ER; Liu, X; Mounts, WM; Rutkowski, JL; Wang, X; Winaver, J; Xu, X; Zhan, Y | 1 |
| Aguilera, A; González-Mateo, G; López-Cabrera, M; Loureiro, J; Maldonado-Rodríguez, A; Martín, P; Mendoza, L; Ortiz, A; Pérez-Lozano, ML; Ruíz-Ortega, M; Sánchez-Madrid, F; Sánchez-Tomero, JA; Sandoval, P; Santamaría, B; Selgas, R | 1 |
| Feldon, SE; Guo, N; Phipps, RP; Woeller, CF | 1 |
| Dai, B; Fu, L; Hua, Z; Liu, Y; Mei, C; Xu, C | 1 |
| Chen, J; Cui, R; Guo, L; Huang, MQ; Li, HM; Miao, ZL; Qin, WB; Wang, YX; Wang, ZN; Wei, XC; Yang, N | 1 |
| Amiri, F; Diep, QN; Iglarz, M; Paradis, P; Schiffrin, EL; Touyz, RM; Viel, EC | 1 |
| Bacon, BR; Brunt, EM; Neuschwander-Tetri, BA; Oliver, D; Wehmeier, KR | 1 |
| De Windt, LJ; Smeets, PJ; Teunissen, BE; Van Bilsen, M; Van der Vusse, GJ; Willemsen, PH | 1 |
| Gao, DF; Hao, GH; Niu, XL; Wang, NP; Wei, J | 1 |
| Bernhardt, C; Bruckert, E; Charlotte, F; Giral, P; Grimaldi, A; Hartemann-Heurtier, A; Jacqueminet, S; Lacorte, JM; Podevin, P; Poynard, T; Ratziu, V; Serfaty, L | 1 |
2 trial(s) available for rosiglitazone and Cirrhosis
| Article | Year |
|---|---|
Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens.
Topics: Biopsy; Blood Glucose; Fatty Liver; Female; Fibrosis; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Liver Function Tests; Male; Middle Aged; Obesity; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Tomography, X-Ray Computed; Transcription Factors | 2004 |
Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.
Topics: Adiponectin; Adult; Aged; Alanine Transaminase; Fatty Liver; Female; Fibrosis; gamma-Glutamyltransferase; Hepatitis; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Necrosis; Placebos; Rosiglitazone; Thiazolidinediones | 2008 |
31 other study(ies) available for rosiglitazone and Cirrhosis
| Article | Year |
|---|---|
Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.
Topics: Animals; Benzothiazoles; Carbon Tetrachloride Poisoning; Cell Line; Drug Discovery; Fibrosis; Hepatocytes; High-Throughput Screening Assays; Humans; Hypoglycemic Agents; Indoles; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Sulfonamides | 2018 |
Inhibition of ACSL4 ameliorates tubular ferroptotic cell death and protects against fibrotic kidney disease.
Topics: Acute Kidney Injury; Animals; Cell Death; Epithelial Cells; Fibrosis; Humans; Mice; Neurodegenerative Diseases; Rosiglitazone | 2023 |
Antifibrotic Effects of the Thiazolidinediones in Eosinophilic Esophagitis Pathologic Remodeling: A Preclinical Evaluation.
Topics: Biopsy; Budesonide; Cells, Cultured; Drug Evaluation, Preclinical; Eosinophilic Esophagitis; Esophagus; Fibrosis; Gene Expression Regulation; Humans; Interleukin-4; Myofibroblasts; Pioglitazone; PPAR gamma; Primary Cell Culture; Rosiglitazone; Signal Transduction; Transforming Growth Factor beta1 | 2020 |
Ultrasound Assisted a Peroxisome Proliferator-Activated Receptor (PPAR)γ Agonist-Loaded Nanoparticle-Microbubble Complex to Attenuate Renal Interstitial Fibrosis.
Topics: Animals; Drug Delivery Systems; Fibrosis; Kidney; Kidney Diseases; Male; Mice; Microbubbles; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer; PPAR gamma; Rats, Sprague-Dawley; Rosiglitazone; Tissue Distribution; Ultrasonography | 2020 |
Protective effect of rosiglitazone on kidney function in high-fat challenged human-CRP transgenic mice: a possible role for adiponectin and miR-21?
Topics: Adipokines; Adiponectin; Animals; Biomarkers; Blood Glucose; C-Reactive Protein; Diet, High-Fat; Fibrosis; Humans; Immunohistochemistry; Inflammation Mediators; Insulin; Kidney; Mice; Mice, Transgenic; MicroRNAs; Protective Agents; Rosiglitazone | 2017 |
Anti-fibrogenic effect of PPAR-γ agonists in human intestinal myofibroblasts.
Topics: Actins; Cells, Cultured; Chromans; Extracellular Matrix Proteins; Fibrosis; Gene Expression; Humans; Intestines; Myofibroblasts; Phosphorylation; PPAR gamma; Proto-Oncogene Proteins c-akt; Rosiglitazone; Smad2 Protein; Thiazolidinediones; Transforming Growth Factor beta1; Troglitazone | 2017 |
Antifibrotic Actions of Peroxisome Proliferator-Activated Receptor γ Ligands in Corneal Fibroblasts Are Mediated by β-Catenin-Regulated Pathways.
Topics: Actins; Animals; beta Catenin; Cats; Chromans; Collagen Type I; Cornea; Fibroblasts; Fibronectins; Fibrosis; Glycogen Synthase Kinase 3 beta; Lithium Chloride; p38 Mitogen-Activated Protein Kinases; Phosphorylation; PPAR gamma; Prostaglandin D2; Pyrvinium Compounds; Receptors, Transforming Growth Factor beta; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transforming Growth Factor beta1; Troglitazone | 2017 |
A PPAR-Gamma Agonist Rosiglitazone Suppresses Fibrotic Response in Human Pterygium Fibroblasts by Modulating the p38 MAPK Pathway.
Topics: Actins; Apoptosis; Blotting, Western; Cells, Cultured; Extracellular Matrix Proteins; Fibrosis; Flow Cytometry; Fluorescent Antibody Technique, Indirect; Humans; Hypoglycemic Agents; Myofibroblasts; p38 Mitogen-Activated Protein Kinases; PPAR gamma; Pterygium; Real-Time Polymerase Chain Reaction; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transforming Growth Factor beta1 | 2017 |
PGC-1α ameliorates kidney fibrosis in mice with diabetic kidney disease through an antioxidative mechanism.
Topics: Animals; Cell Line; Diabetic Nephropathies; Fibrosis; Kidney; Mesangial Cells; Mice; Mice, Inbred C57BL; Mitochondria; Nuclear Respiratory Factor 1; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Podocytes; PPAR gamma; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Rosiglitazone; Serum Albumin; Superoxide Dismutase; Thiazolidinediones; Up-Regulation | 2018 |
Joint contracture is reduced by intra-articular implantation of rosiglitazone-loaded hydrogels in a rabbit model of arthrofibrosis.
Topics: Animals; Cells, Cultured; Contracture; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Fibroblasts; Fibrosis; Humans; Hypoglycemic Agents; Polyesters; Polyethylene Glycols; Rabbits; Rosiglitazone; Tissue Scaffolds | 2018 |
Protective effect of rosiglitazone on chronic renal allograft dysfunction in rats.
Topics: Animals; Anti-Inflammatory Agents; Chronic Disease; Disease Models, Animal; Epithelial-Mesenchymal Transition; Fibrosis; Graft Rejection; Humans; Kidney; Kidney Transplantation; Macrophages; Male; PPAR gamma; Rats; Rats, Inbred Lew; Rosiglitazone; Signal Transduction; Transforming Growth Factor beta | 2019 |
Involvement of lncR-30245 in Myocardial Infarction-Induced Cardiac Fibrosis Through Peroxisome Proliferator-Activated Receptor-γ-Mediated Connective Tissue Growth Factor Signalling Pathway.
Topics: Animals; Benzamides; Cell Proliferation; Collagen; Connective Tissue Growth Factor; Fibroblasts; Fibrosis; Heart Diseases; Mice, Inbred C57BL; Models, Animal; Myocardial Infarction; PPAR gamma; Pyridines; RNA, Long Noncoding; Rosiglitazone; Stroke Volume; Transforming Growth Factor beta1; Up-Regulation | 2019 |
Rosiglitazone Treatment Prevents Postoperative Fibrosis in a Rabbit Model of Glaucoma Filtration Surgery.
Topics: Actins; Animals; Autophagy; Blotting, Western; Conjunctiva; Connective Tissue Growth Factor; Disease Models, Animal; Fibroblasts; Fibrosis; Glaucoma; Hypoglycemic Agents; Intraocular Pressure; Male; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Polymerase Chain Reaction; Postoperative Complications; Rabbits; Real-Time Polymerase Chain Reaction; Rosiglitazone; Tenon Capsule; Trabeculectomy; Transforming Growth Factor beta1 | 2019 |
Effects of rosiglitazone/PHBV drug delivery system on postoperative fibrosis in rabbit glaucoma filtration surgery model.
Topics: Animals; Cicatrix; Conjunctiva; Cornea; Disease Models, Animal; Drug Delivery Systems; Fibrosis; Filtering Surgery; Glaucoma; Intraocular Pressure; Polyesters; Rabbits; Rosiglitazone; Wound Healing | 2019 |
Inhibitory effects of PPARγ ligands on TGF-β1-induced corneal myofibroblast transformation.
Topics: Actins; Animals; Cats; Cell Line, Transformed; Cell Nucleus; Chromans; Collagen Type I; Cornea; Fibronectins; Fibrosis; Humans; Ligands; Myofibroblasts; p38 Mitogen-Activated Protein Kinases; Phosphorylation; PPAR gamma; Prostaglandin D2; Protein Kinase Inhibitors; Protein Transport; Rosiglitazone; Signal Transduction; Smad Proteins; Thiazolidinediones; Transforming Growth Factor beta1; Troglitazone; Wound Healing | 2014 |
Rosiglitazone attenuates atrial structural remodeling and atrial fibrillation promotion in alloxan-induced diabetic rabbits.
Topics: Alloxan; Animals; Atrial Fibrillation; Atrial Function, Left; Atrial Remodeling; Biomarkers; Cardiac Pacing, Artificial; Diabetes Mellitus, Experimental; Fibrosis; Heart Atria; Hypoglycemic Agents; Inflammation Mediators; Oxidative Stress; Rabbits; Rosiglitazone; Thiazolidinediones; Time Factors | 2014 |
Concomitant use of rapamycin and rosiglitazone delays the progression of polycystic kidney disease in Han:SPRD rats: a study of the mechanism of action.
Topics: Animals; Cell Line; Cell Proliferation; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Epithelial Cells; Fibrosis; G1 Phase Cell Cycle Checkpoints; Humans; Kidney; Lipids; Male; Phosphorylation; Polycystic Kidney, Autosomal Dominant; PPAR gamma; Proto-Oncogene Proteins c-akt; Rats, Sprague-Dawley; Renal Agents; Ribosomal Protein S6 Kinases, 70-kDa; Rosiglitazone; Signal Transduction; Sirolimus | 2018 |
Renal tubular epithelium-targeted peroxisome proliferator-activated receptor-γ maintains the epithelial phenotype and antagonizes renal fibrogenesis.
Topics: Animals; Cells, Cultured; Fibrosis; Humans; Kidney; Kidney Diseases; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; Phenotype; PPAR gamma; Prostaglandin D2; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transforming Growth Factor beta1; Urothelium | 2016 |
Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma.
Topics: Adipocytes; Animals; Antibiotics, Antineoplastic; Bleomycin; Cell Differentiation; Cell Movement; Collagen; Female; Fibrosis; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression; Hypoglycemic Agents; Immunohistochemistry; Inflammation; Mice; Mice, Inbred BALB C; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Scleroderma, Systemic; Stem Cells; Thiazolidinediones; Transforming Growth Factor beta1 | 2009 |
Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor.
Topics: Animals; Body Weight; Cardiomyopathies; Connective Tissue Growth Factor; Diabetes Mellitus, Type 2; Disease Models, Animal; Echocardiography; Fibrosis; Glucose Tolerance Test; Male; Myocardium; PPAR gamma; Rats; Rats, Inbred OLETF; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Rosiglitazone; Thiazolidinediones | 2010 |
Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts.
Topics: Actins; Adult; Cells, Cultured; Female; Fibroblasts; Fibrosis; Humans; Male; Middle Aged; Phenotype; PPAR gamma; Rosiglitazone; Scleroderma, Localized; Skin; Thiazolidinediones | 2010 |
Ameliorative role of rosiglitazone in hyperhomocysteinemia-induced experimental cardiac hypertrophy.
Topics: Animals; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrosis; Homocysteine; Hyperhomocysteinemia; Hypertrophy, Left Ventricular; Male; Methionine; Oxidative Stress; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones | 2010 |
Rosiglitazone reverses cardiac adverse remodeling (fibrosis and vascularization) in perinatal low protein rat offspring.
Topics: Animals; Blood Pressure; Cardiovascular Diseases; Diet, Protein-Restricted; Fibrosis; Heart; Hypoglycemic Agents; Male; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Ventricular Remodeling | 2010 |
Pharmacogenomic, physiological, and biochemical investigations on safety and efficacy biomarkers associated with the peroxisome proliferator-activated receptor-gamma activator rosiglitazone in rodents: a translational medicine investigation.
Topics: Animals; Biomarkers; Body Weight; Diabetes Mellitus; Echocardiography; Fibrosis; Gene Expression Regulation; Heart Failure; Hemodynamics; Hypoglycemic Agents; Immunohistochemistry; Myocarditis; Myocardium; Organ Size; PPAR gamma; Rats; Rats, Inbred Lew; Rats, Zucker; RNA; Rosiglitazone; Thiazolidinediones; Translational Research, Biomedical | 2010 |
PPAR-γ agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage.
Topics: Animals; Dialysis Solutions; Epithelial Cells; Epithelial-Mesenchymal Transition; Epithelium; Fibrosis; Glucose; Glycation End Products, Advanced; Immunity, Cellular; Inflammation; Mice; Peritoneal Dialysis; Peritoneum; PPAR gamma; Rosiglitazone; T-Lymphocytes; Thiazolidinediones | 2010 |
Peroxisome proliferator-activated receptor gamma ligands inhibit transforming growth factor-beta-induced, hyaluronan-dependent, T cell adhesion to orbital fibroblasts.
Topics: Cell Adhesion; Cells, Cultured; Fibroblasts; Fibrosis; Glucuronosyltransferase; Humans; Hyaluronan Synthases; Hyaluronic Acid; Hypoglycemic Agents; Inflammation; Ligands; Orbit; Orbital Diseases; Pioglitazone; PPAR gamma; RNA, Messenger; Rosiglitazone; T-Lymphocytes; Thiazolidinediones; Transforming Growth Factor beta | 2011 |
Rosiglitazone inhibits transforming growth factor-β1 mediated fibrogenesis in ADPKD cyst-lining epithelial cells.
Topics: Cells, Cultured; Collagen Type I; Cysts; Enzyme Activation; Epithelial Cells; Female; Fibronectins; Fibrosis; Humans; Kidney Tubules; Male; MAP Kinase Signaling System; Middle Aged; Polycystic Kidney, Autosomal Dominant; PPAR gamma; RNA, Small Interfering; Rosiglitazone; Smad2 Protein; Thiazolidinediones; Time Factors; Transforming Growth Factor beta1 | 2011 |
The intervention effect of Rosiglitozone in ovarian fibrosis of PCOS rats.
Topics: Animals; Connective Tissue Growth Factor; Female; Fibrosis; Hypoglycemic Agents; Ovary; Polycystic Ovary Syndrome; Random Allocation; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta | 2012 |
Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension.
Topics: Animals; Blood Pressure; Body Weight; Cardiomegaly; Collagen; Desoxycorticosterone; Endothelin-1; Endothelins; Fenofibrate; Fibrosis; Heart; Heart Ventricles; Hypertension; Myocardium; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Ventricular Remodeling | 2003 |
Activation of PPARdelta inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts.
Topics: Animals; Animals, Newborn; Cell Differentiation; Cell Proliferation; Cells, Cultured; Collagen; Fibroblasts; Fibrosis; Humans; Immunohistochemistry; Ligands; Myocytes, Cardiac; Peroxisome Proliferators; PPAR alpha; PPAR delta; PPAR gamma; Pyrimidines; Rats; Rats, Inbred Lew; Rosiglitazone; Thiazoles; Thiazolidinediones; Transduction, Genetic | 2007 |
Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts.
Topics: Angiotensin II; Animals; Cell Proliferation; Dose-Response Relationship, Drug; Extracellular Matrix; Fibroblasts; Fibrosis; Gene Expression Regulation; Male; Myocardium; Plasminogen Activator Inhibitor 1; PPAR gamma; Prostaglandin D2; Rats; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transforming Growth Factor beta1 | 2008 |